Research programme: next-generation Wnt signalling pathway inhibitors - Eisai/Verastem Oncology

Drug Profile

Research programme: next-generation Wnt signalling pathway inhibitors - Eisai/Verastem Oncology

Latest Information Update: 11 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd; Verastem
  • Developer Eisai Co Ltd; Verastem Oncology
  • Class Small molecules
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer; Cancer

Most Recent Events

  • 03 May 2018 Verastem is now operating as Verastem Oncology
  • 16 Jul 2016 No recent reports of development identified for research development in Breast-cancer in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top